Role of nitric oxide production in anaphylaxis and its relevance for the treatment of anaphylactic hypotension with methylene blue

Annals of Allergy, Asthma and Immunology

Volumn 99, Issue 4, 2007, Pages 306-313

  Evora, Paulo R B ^a   Simon, Michael R ^b,c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMINOPHYLLINE; ATROPINE; CATECHOLAMINE; CORTICOSTEROID; CYCLIC GMP; DIPYRONE; DOPAMINE; GUANYLATE CYCLASE; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; IODINE DERIVATIVE; LEUKOTRIENE; LIDOCAINE; METHYLENE BLUE; METHYLPREDNISOLONE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NORADRENALIN; PENICILLIN G; POLYAMIDE; PROTAMINE; SUXAMETHONIUM; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR;

ABDOMINAL PAIN; AIRWAY RESISTANCE; ANAPHYLAXIS; BRADYCARDIA; BRONCHOSPASM; CARDIOPULMONARY ARREST; CYANOSIS; DRUG HALF LIFE; EDEMA; ENZYME ACTIVATION; ENZYME INHIBITION; FACE EDEMA; FEVER; FLUSHING; GLOTTAL EDEMA; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; HYPOTENSION; HYPOXEMIA; INHIBITION KINETICS; MEDLINE; METHEMOGLOBINEMIA; NAUSEA; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SHOCK; SIDE EFFECT; SMOOTH MUSCLE RELAXATION; SYSTEMIC VASCULAR RESISTANCE; TONGUE EDEMA; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT RESPONSE; VASODILATATION; VOMITING;

EID: 35448971487     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60545-5     Document Type: Review

References (102)

1. Lieberman PL. Anaphylaxis and anaphylactoid reactions. In: Adkinson NF Jr, Yuninger JW, Busse WW, Bochner BS, Holgate ST, Simons FER, eds. Allergy Principles and Practice. 6th ed. Philadelphia, PA: Mosby; 2003:1497-1522.
2. Fahmy NR. Hemodynamics, plasma histamine, and catecholamine concentrations during an anaphylactoid reaction to morphine. Anesthesiology. 1981;55:329-331.
3. Nicolas F, Villers D, Blanloeil Y. Hemodynamic pattern in anaphylactic shock with cardiac arrest. Crit Care Med. 1984;12:144-145.
4. Moss J, Fahmy NR, Sunder N, Beaven MA. Hormonal and hemodynamic profile of an anaphylactic reaction in man. Circulation. 1981;63:210-213.
5. Winbery SL, Lieberman PL. Histamine and antihistamines in anaphylaxis. Clin Allergy Immunol. 2002;17:287-317.
6. Enjeti S, Bleecker ER, Smith PL, Rabson J, Permutt S, Traystman RJ. Hemodynamic mechanisms in anaphylaxis. Circ Shock. 1983;11:297-309.
7. 2 -receptor antagonists]. Anaesthesist. 1977;26:644-648.
8. Philbin DM, Moss J, Akins CW, Rosow CE, Kono K, Schneider RC, VerLee TR, Savarese JJ. The use of H1 and H2 histamine antagonists with morphine anesthesia: a double-blind study. Anesthesiology. 1981;55:292-296.
9. Kaliner M, Sigler R, Summers R, Shelhamer JH. Effects of infused histamine: analysis of the effects of H-1 and H-2 histamine receptor antagonists on cardiovascular and pulmonary responses. J Allergy Clin Immunol. 1981;68:365-371.
10. Lorenz W, Doenicke A, Schoning B, Ohmann C, Grote B, Neugebauer E. Definition and classification of the histamine-release response to drugs in anesthesia and surgery: studies in the conscious human subject. Klin Wochenschr. 1982;60:896-913.
11. Kaliner M, Shelhamer JH, Ottesen EA. Effects of infused histamine: correlation of plasma histamine levels and symptoms. J Allergy Clin Immunol. 1982;69:283-289.
12. Owen DA, Harvey CA, Boyce MJ. Effects of histamine on the circulatory system. Klin Wochenschr. 1982;60:972-977.
13. Tryba M, Zevounou F, Zenz M. Prophylaxe anaphylakoider Reaktionen mit Promethazin und Cimetidin bei intramuskularer Applikation. Untersuchungun am Histamininfusions - Model [Prevention of anaphylactoid reactions using intramuscular promethazine and cimetidine studies of a histamine infusion model]. Anaesthesist. 1984;33:218-223.
14. Dachman WD, Bedarida G, Blaschke TF, Hoffman BB. Histamine-induced venodilation in human beings involves both H1 and H2 receptor subtypes. J Allergy Clin Immunol. 1994;93:606-614.
15. Shi W, Wang CG, Dandurand RJ, Eidelman DH, Michel RP. Differential responses of pulmonary arteries and veins to histamine and 5-HT in lung explants of guinea-pigs. Br J Pharmacol. 1998;123:1525-1532.
16. Daneshmand MA, Keller RS, Canver MC, Canver AC, Canver CC. Histamine H1 and H2 receptor-mediated vasoreactivity of human internal thoracic and radial arteries. Surgery. 2004;136:458-463.
17. Lockwood JM, Wilkins BW, Halliwill JR. H1 receptor-mediated vasodilatation contributes to postexercise hypotension. J Physiol. 2005;563(pt 2):633-642.
18. Lau WH, Kwan YW, Au AL, Cheung WH. An in vitro study of histamine on the pulmonary artery of the Wistar-Kyoto and spontaneously hypertensive rats. Eur J Pharmacol. 2003;470:45-55.
19. Kawada T, Ishibashi T, Sasage H, Kato K, Imai S. Modification by LY83583 and methylene blue of relaxation induced by nitric oxide, glyceryl trinitrate, sodium nitroprusside and atriopeptin in aorta of the rat, guinea-pig and rabbit. Gen Pharmacol. 1994;25:1361-1371.
20. Friebe A, Koesling D. Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res. 2003;93:96-105.
21. Van de Voorde J, Leusen I. Role of the endothelium in the vasodilator response of rat thoracic aorta to histamine. Eur J Pharmacol. 1983;87:113-120.
22. Krstic MK, Stepanovic RM, Krstic SK, Katusic ZS. Endothelium-dependent relaxation of the rat renal artery caused by activation of histamine H1-receptors. Pharmacology. 1989;38:113-120.
23. Toda N. Endothelium-dependent relaxation induced by angiotensin II and histamine in isolated arteries of dog. Br J Pharmacol. 1984;81:301-307.
24. Ortiz JL, Labat C, Norel X, Gorenne I, Verley J, Brink C. Histamine receptors on human isolated pulmonary arterial muscle preparations: effects of endothelial cell removal and nitric oxide inhibitors. J Pharmacol Exp Ther. 1992;260:762-776.
25. Payne GW, Madri JA, Sessa WC, Segal SS. Abolition of arteriolar dilation but not constriction to histamine in cremaster muscle of eNOS-/- mice. Am J Physiol Heart Circ Physiol. 2003;285:H493-H498.
26. Li H, Burkhardt C, Heinrich UR, Brausch I, Xia N, Forstermann U. Histamine upregulates gene expression of endothelial nitric oxide synthase in human vascular endothelial cells. Circulation. 2003;107:2348-2354.
27. Kishi F, Nakaya Y, Takahashi A, Miyoshi H, Nomura M, Saito K. Intracellular and extracellular Ca2+ regulate histamine-induced release of nitric oxide in vascular endothelial cells as shown with sensitive and selective nitric oxide electrodes. Pharmacol Res. 1996;33:123-126.
28. Rosenkranz-Weiss P, Sessa WC, Milstien S, Kaufman S, Watson CA, Pober JS. Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells: elevations in tetrahydrobiopterin levels enhance endothelial nitric oxide synthase specific activity. J Clin Invest. 1994;93:2236-2243.
29. Lantoine F, Iouzalen L, Devynck MA, Millanvoye-Van Brussel E, David-Dufilho M. Nitric oxide production in human endothelial cells stimulated by histamine requires Ca2+ influx. Biochem J. 1998;330(pt 2):695-699.
30. Champion HC, Kadowitz PJ. R-(-)-alpha-methyl-histamine has nitric oxide-mediated vasodilator activity in the mesenteric vascular bed of the cat. Eur J Pharmacol. 1998;343:209-216.
31. Champion HC, Kadowitz PJ. NO release and the opening of K+ATP channels mediate vasodilator responses to histamine in the cat. Am J Physiol. 1997;273(2 pt 2):H928-H937.
32. Yuan Y, Granger HJ, Zawieja DC, DeFily DV, Chilian WM. Histamine increases venular permeability via a phospholipase C-NO synthase-guanylate cyclase cascade. Am J Physiol. 1993;264(5 pt 2):H1734-H1739.
33. Ayajiki K, Okamura T, Toda N. Involvement of nitric oxide in endothelium-dependent, phasic relaxation caused by histamine in monkey cerebral arteries. Jpn J Pharmacol. 1992;60:357-362.
34. Haefliger IO, Flammer J, Luscher TF. Nitric oxide and endothelin-1 are important regulators of human ophthalmic artery. Invest Ophthalmol Vis Sci. 1992;33:2340-2343.
35. Mayhan WG. Nitric oxide accounts for histamine-induced increases in macromolecular extravasation. Am J Physiol. 1994;266(6 pt 2):H2369-H2373.
36. Choi IW, Kim YS, Kim DK, et al. Platelet-activating factor-mediated NF-kappaB dependency of a late anaphylactic reaction. J Exp Med. 2003;198:145-151.
37. Finkelman FD, Rothenberg ME, Brandt EB, Morris SC, Strait RT. Molecular mechanisms of anaphylaxis: lessons from studies with murine models. J Allergy Clin Immunol. 2005;115:449-457.
38. Walsh LJ, Trinchieri G, Waldorf HA, Whitaker D, Murphy GF. Human dermal mast cells contain and release tumor necrosis factor alpha, which induces endothelial leukocyte adhesion molecule 1. Proc Natl Acad Sci USA. 1991;88:4220-4224.
39. Pawloski JR, Chapnick BM. Leukotrienes C4 and D4 are potent endothelium-dependent relaxing agents in canine splanchnic venous capacitance vessels. Circ Res. 1993;73:395-404.
40. Moritoki H, Hisayama T, Takeuchi S, Miyano H, Kondoh W. Involvement of nitric oxide pathway in the PAF-induced relaxation of rat thoracic aorta. Br J Pharmacol. 1992;107:196-201.
41. G-nitro- L-arginine on shock induced by endotoxin and by platelet activating factor in dogs. Eur J Pharmacol. 1993;250:465-467.
42. Cauwels A, Janssen B, Buys E, Sips P, Brouckaert P. Anaphylactic shock depends on PI3K and eNOS-derived NO. J Clin Invest. 2006;116:2244-2251.
43. Thiemermann C, Wu C-C, Szabo C, Perretti M, Vane JR. Role of tumour necrosis factor in the induction of nitric oxide synthase in a rat model of endotoxin shock. Br J Pharmacol. 1993;110:177-182.
44. Fahey TJ 3rd, Yoshioka T, Shires GT, Fantini GA. The role of tumor necrosis factor and nitric oxide in the acute cardiovascular response to endotoxin. Ann Surg. 1996;223:63-69.
45. Lowenstein CJ, Michel T. What's in a name? eNOS and anaphylactic shock. J Clin Invest. 2006;116:2075-2078.
46. Gilchrist M, McCauley SD, Befus AD. Expression, localization, and regulation of NOS in human mast cell lines: effects on leukotriene production. Blood. 2004;104:462-469.
47. G-nitro-L-arginine-methyl ester, improves survival in anaphylactic shock. Eur J Pharmacol. 1991;203:125-127.
48. Osada S, Ichiki H, Oku H, Ishiguro K, Kunitomo M, Semma M. Participation of nitric oxide in mouse anaphylactic hypotension. Eur J Pharmacol. 1994;252:347-350.
49. Mitsuhata H, Saitoh J, Takeuchi H, Hasome N, Horiguchi Y, Shimizu R. Production of nitric oxide in anaphylaxis in rabbits. Shock. 1994;2:381-384.
50. Buzato MA, Viaro F, Piccinato CE, Evora PRB. The use of methylene blue in the treatment of anaphylactic shock induced by compound 48/80: experimental studies in rabbits. Shock. 2005;23:582-587.
51. T type of human lung mast cell. J Allergy Clin Immunol. 2005;115:1162-1168.
52. Ennis M, Lorenz W, Gerland W, Heise J. Isolation of mast cells from rabbit lung and liver: comparison of histamine release induced by the hypnotics Althesin and propanidid. Agents Actions. 1987;20:219-222.
53. Mitsuhata H, Saito J, Hasome N, Takeuchi H, Horiguchi Y, Shimizu R. Nitric oxide inhibition is detrimental to cardiac function and promotes bronchospasms in anaphylaxis in rabbits. Shock. 1995;4:143-148.
54. Evora PR, Pearson PJ, Schaff HV. Protamine induces endothelium-dependent vasodilatation of the pulmonary artery. Ann Thorac Surg. 1995;60:405-410.
55. Raikar GV, Hisamochi K, Raikar BL, Schaff HV. Nitric oxide inhibition attenuates systemic hypotension produced by protamine. J Thorac Cardiovasc Surg. 1996;111:1240-1246; discussion 1246-1247.
56. ω-nitro-L- arginine-methyl ester, attenuates hypotension but does not improve cardiac depression in anaphylaxis in dogs. Shock. 1995;3:447-453.
57. Saitoh J, Mitsuhata H, Takeuchi H, Hasome N, Shimizu R. In vivo production of nitric oxide in the canine heart in IgE-mediated anaphylaxis. Shock. 1996;6:66-70.
58. Rolla G, Nebiolo F, Guida G, Heffler E, Bommarito L, Bergia R. Level of exhaled nitric oxide during human anaphylaxis. Ann Allergy Asthma Immunol. 2006;97:264-265.
59. Gupta A, Lin RY, Pesola GR, et al. Nitric oxide levels in patients with acute allergic reactions. Internet J Asthma Allergy Immunol. 2004;3:1.
60. Zeballos GA, Bernstein RD, Thompson CI, et al. Pharmacodynamics of plasma nitrate/nitrite as an indication of nitric oxide formation in conscious dogs. Circulation. 1995;91:2982-2988.
61. Schummer W, Schummer C, Wippermann J, Fuchs J. Anaphylactic shock: is vasopressin the drug of choice? Anesthesiology. 2004;101:1025-1027.
62. Zaloga GP, Delacey W, Holmboe E, Chernow B. Glucagon reversal of hypotension in a case of anaphylactoid shock. Ann Intern Med. 1986;105:65-66.
63. Harbrecht BG, Wirant EM, Kim YM, Billiar TR. Glucagon inhibits hepatocyte nitric oxide synthesis. Arch Surg. 1996;131:1266-1272.
64. Cell-to-cell signaling: hormones and receptors. In: Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J, eds. Molecular Cell Biology. New York, NY: WH Freeman & Co; 2000:chap 20.
65. Morello JP, Salahpour A, Laperriere A, et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest. 2000;105:887-895.
66. Smith FS, Ceppi ED, Titheradge MA. Inhibition of cytokine-induced inducible nitric oxide synthase expression by glucagon and cAMP in cultured hepatocytes. Biochem J. 1997;326(Pt 1):187-192.
67. Harbrecht BG, Taylor BS, Xu Z, Ramalakshmi S, Ganster RW, Geller DA. cAMP inhibits inducible nitric oxide synthase expression and NF-kappaB-binding activity in cultured rat hepatocytes. J Surg Res. 2001;99:258-264.
68. Barnes RD, Ward LE, Frank KP, Tyce GM, Hunter LW, Rorie DK. Nitric oxide modulates evoked catecholamine release from canine adrenal medulla. Neuroscience. 2001;104:1165-1173.
69. Ward LE, Hunter LW, Grabau CE, Tyce GM, Rorie DK. Nitric oxide reduces basal efflux of catecholamines from perfused dog adrenal glands. J Auton Nerv Syst. 1996;61:235-242.
70. Kolo LL, Westfall TC, Macarthur H. Nitric oxide decreases the biological activity of norepinephrine resulting in altered vascular tone in the rat mesenteric arterial bed. Am J Physiol Heart Circ Physiol. 2004;286:H296-H303.
71. Stark BJ, Sullivan TJ. Biphasic and protracted anaphylaxis. J Allergy Clin Immunol. 1986;78(1 pt 1):76-83.
72. Smith PL, Kagey-Sobotka A, Bleecker ER, et al. Physiologic manifestations of human anaphylaxis. J Clin Invest. 1980;66:1072-1080.
73. Preiser J-C, Lejeune P, Roman A, et al. Methylene blue administration in septic shock: a clinical trial. Crit Care Med. 1995;23:259-264.
74. Donati A, Conti G, Loggi S, et al. Does methylene blue administration to septic shock patients affect vascular permeability and blood volume? Crit Care Med. 2002;30:2271-2277.
75. Viaro F, Dalio MB, Evora PR. Catastrophic cardiovascular adverse reactions to protamine are nitric oxide/cyclic guanosine monophosphate dependent and endothelium mediated: should methylene blue be the treatment of choice? Chest. 2002;122:1061-1066.
76. Evora PRB, Viaro F. The guanylyl cyclase inhibition by MB as vasoplegic circulatory shock therapeutical target. Curr Drug Targets. 2006;7:1195-1204.
77. Evora PR, Roselino CH, Schiaveto PM. Methylene blue in anaphylactic shock [letter]. Ann Emerg Med. 1997;30:240.
78. Oliveira Neto AM, Duarte NM, Vicente WV, Viaro F, Evora PR. Methylene blue: an effective treatment for contrast medium-induced anaphylaxis. Med Sci Monit. 2003;9:CS102-CS106.
79. Duarte NM, Oliveira Neto AM, Evora PRB. Utilização endovenosa do azul de metileno no tratamento do choque anafilático [Utilization of intravenous methylene blue in the treatment of anaphylactic shock] [abstract]. Arq Bras Cardiol. 2002;79(suppl III):73.
80. Rodrigues JM, Pazin Filho A, Rodrigues AJ, Vicente WV, Evora PRB. Methylene blue for clinical anaphylaxis treatment: a case report .. Sao Paulo Med J. 2007;125:60-62.
81. Mestriner Stocche R, Garcia LV, Paulino dos Reis M, Klamt JG, Evora PRB. Uso do azul de metileno no tratamento de choque anafilatico durante anesthesia: relato de caso. [Methylene blue to treat anaphylaxis during anesthesia: case report]. Rev Bras Anestesiol. 2004;54:809-814.
82. Sheth SS, Del Duca D, Ergina P, Clarke AE. Methylene blue as a treatment for refractory anaphylaxis [abstract]. J Allergy Clin Immunol. 2007;119 (1 pt 2):S33.
83. Sheth SS, Del Duca D, Ergina P, Clarke A. Methylene blue as a treatment for refractory anaphylaxis. Paper presented at: American Academy of Allergy, Asthma and Immunology Annual Meeting; February 23-27, 2007; San Diego, CA. Posters2View Marathon Multimedia, Faribault, MN.
84. Burrows GE. Methylene blue: effects and disposition in sheep. J Vet Pharmacol Ther. 1984;7:225-231.
85. Menardi AC, Viaro F, Vicente WV, Rodrigues AJ, Evora PR. Hemodynamic and vascular endothelium function studies in healthy pigs after intravenous bolus infusion of methylene blue. Arq Bras Cardiol. 2006;87:525-532.
86. Peter C, Hongwan D, Kupfer A, Lauterburg BH. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol. 2000;56:247-250.
87. Clifton J II, Leikin JB. Methylene blue. Am J Ther. 2003;10:289-291.
88. Burnakis TG. Inadvertent substitution of methylene blue for indigo carmine to detect premature rupture of membranes. Hosp Pharm. 1995;30:336-338.
89. Whitwam JG, Taylor AR, White JM. Potential hazard of methylene blue. Anaesthesia. 1979;34:181-182.
90. Breault DT, Fisher D, Wiley JF II, Caulkins K, Caperino L. Methylene blue toxicity after oral exposure in an infant [abstract]. J Toxicol Clin Toxicol. 1997;35:504.
91. Bilgin H, Ozcan B, Bilgin T. Methemoglobinemia induced by methylene blue pertubation during laparoscopy. Acta Anaesthesiol Scand. 1998;42:594-595.
92. Dudley NE. Methylene blue for rapid identification of the parathyroids. BMJ. 1971;3:680-168.
93. Gordon DL, Airan MC, Thomas W, et al. Parathyroid identification by methylene blue infusion. Br J Surg. 1975;62:747-749.
94. Bambach CP, Reeve TS. Parathyroid identification by methylene blue infusion. Aust N Z J Surg. 1978;48:314-317.
95. Wheeler MH, Wade JHS. Intraoperative identification of parathyroid glands: appraisal of methylene blue staining. Am J Surg. 1982;143:713-716.
96. Derom AF, Wallaert PC, Janzing HM, Derom FE. Intraoperative identification of parathyroid glands with methylene blue infusion. Am J Surg. 1993;165:380-382.
97. Meekin GK. Intraoperative use of methylene blue to localize parathyroid adenoma. Laryngoscope. 1998;108:772-773.
98. Zulian GB, Tullen E, Maton B. Methylene blue for ifosfamide-associated encephalopathy. N Engl J Med. 1995;332:1239-1240.
99. Martindale SJ, Stedeford JC. Neurological sequelae following methylene blue injection for parathyroidectomy. Anaesthesia. 2003;58:1041-1042.
100. Bach KK, Lindsay FW, Berg LS, Howard RS. Prolonged postoperative disorientation after methylene blue infusion during parathyroidectomy. Anesth Analg. 2004;99:1573-1574.
101. Kessler MR, Eide T, Humayun B, Poppers PJ. Spurious pulse oximeter desaturation with methylene blue injection. Anesthesiology. 1986;65:435-436. Erratum in: Anesthesiology. 1987;66:701.
102. Kirlangitis JJ, Middaugh RE, Zablocki A, Rodriquez F. False indication of arterial oxygen desaturation and methemoglobinemia following injection of methylene blue in urological surgery. Mil Med. 1990;155:260-262.